Anticonvulsants Global Market Report 2024

The anticonvulsants market has grown steadily in recent years. It will grow from $18.39 billion in 2023 to $19.08 billion in 2024 at a compound annual growth rate (CAGR) of 3.7%. The growth observed in the historical period can be attributed to several factors, including the increased prevalence of epilepsy, advancements in diagnostic capabilities, the expansion of indications for anticonvulsants, a focus on personalized medicine, and heightened awareness and education regarding the treatment of seizure disorders. These factors collectively contributed to the development and adoption of anticonvulsant medications during this period.

The anticonvulsants market is expected to see steady growth in the next few years. It will grow to $21.75 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%. The anticipated growth in the forecast period can be attributed to several factors, including the ongoing increase in epilepsy cases, expanding applications in neuropsychiatry, the development of new anticonvulsant agents, a growing emphasis on mental health, and global health initiatives. Major trends expected in the forecast period include the development of pediatric applications and formulations, a shift towards extended-release formulations, increased adoption of generic versions of anticonvulsants, integration with digital health solutions, and ongoing research on the neuroprotective effects of these medications.

The upsurge in the prevalence of epilepsy is poised to propel the expansion of the anticonvulsants market in the foreseeable future. Epilepsy stands as a prevalent neurological disorder affecting the brain and often resulting in seizures. This chronic and non-communicable brain ailment affects individuals across all age groups. Anticonvulsants, a class of medications, are utilized to suppress seizures among individuals with epilepsy. They assist in managing epilepsy symptoms by curtailing abnormal electrical activity in the brain, which triggers seizures, although they do not offer a definitive cure for the condition. For instance, data from the World Health Organization in February 2023 revealed an estimated annual diagnosis of epilepsy in approximately 5 million individuals worldwide. In high-income countries, around 49 per 0.1 million people are diagnosed with epilepsy yearly, while in low- and middle-income countries, this figure escalates to as high as 139 per 0.1 million individuals. Hence, the escalating prevalence of epilepsy significantly propels the growth trajectory of the anticonvulsants market.

The burgeoning geriatric populace is anticipated to drive the expansion of the anticonvulsant market in the forthcoming years. The geriatric demographic pertains to the segment encompassing elderly individuals, typically defined as those aged 65 and above. Anticonvulsants play a pivotal role within this demographic, especially in managing seizures and epilepsy - common conditions among elderly individuals. For instance, projections from the World Health Organization in October 2022 indicate that by 2030, one in every six individuals globally will be aged 60 or older, totaling 1.4 billion people, up from 1 billion in 2020. Additionally, the global population aged 60 and older is expected to double by 2050, reaching 2.1 billion individuals. Notably, during the period from 2020 to 2050, there will be a surge of 426 million individuals aged 80 or older. Therefore, the swelling geriatric population significantly propels the expansion of the anticonvulsant market.

Product development emerges as a prominent trend gaining momentum within the anticonvulsants market. Leading companies in this sector are dedicatedly focused on innovating new products to fortify their market position and attain a competitive edge. For instance, Lupin Limited, an India-based pharmaceutical entity, introduced Rufinamide tablets USP, 200 mg and 400 mg, through an abbreviated new drug application in December 2022. Rufinamide, an anticonvulsant drug, is employed in conjunction with other medications to manage seizures in individuals afflicted with Lennox-Gastaut syndrome, a severe form of epilepsy characterized by varied seizures, behavioral disruptions, and developmental delays, typically originating in childhood.

Significant emphasis is placed on the introduction and approval of advanced drug solutions by major players operating in the anticonvulsants market to secure a competitive advantage. These novel drug solutions, upon approval by national regulatory bodies, aim to notably impact the availability of advanced therapies for patients grappling with seizures related to diverse syndromes. For instance, in March 2022, UCB, a Belgium-based biopharmaceutical firm, announced the approval by the U.S. Food and Drug Administration (FDA) for FINTEPLA (fenfluramine) oral solution CIV. This approval caters to treating seizures linked to Lennox-Gastaut syndrome in patients aged two years and above. Fenfluramine demonstrates efficacy in managing challenging seizure types such as drop seizures, characterized by sudden loss of muscular tone, leading to a limp state and an elevated risk of falling and injury. Fenfluramine, working through a distinct mechanism, complements and differs from existing epileptic drugs, enabling its continued use alongside current antiseizure regimens. The clinical trials evidenced statistically significant enhancements in patients with LGS when utilizing fenfluramine based on the Clinical Global Impression Scale (CG-I) in the global placebo-controlled phase 3 trial.

In May 2021, Jazz Pharmaceuticals Inc., an Ireland-based biopharmaceutical company, successfully acquired GW Pharmaceuticals plc for a total of $7.6 billion. This strategic acquisition serves to broaden, diversify, and enrich Jazz's portfolio business strategy by incorporating complementary therapies into its commercial portfolio and innovative pipeline. Additionally, the acquisition strengthens Jazz's neuroscience business through the addition of Epidiolex, a cannabis-based epilepsy treatment developed by GW Pharmaceuticals plc. The latter, headquartered in the UK, is a pharmaceutical company primarily engaged in the manufacturing of anticonvulsant medications.

Major companies operating in the anticonvulsants market report are Eisai Co Ltd., GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services Inc ., Novartis AG, Jazz Pharmaceuticals Inc., UCB SA, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc., Sanofi SA, Zydus Lifesciences Ltd., Lupin Limited, Ratiopharm Group, Kannalife Inc., Neuropathix Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Mylan N.V., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals plc, AstraZeneca plc, Glenmark Pharmaceuticals Limited, Laurus Labs Limited, Biocon Limited, Recordati S.p.A., Neurocrine Biosciences Inc.

North America was the largest region in the Anticonvulsants market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global anticonvulsants market report during the forecast period. The regions covered in the anticonvulsants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anticonvulsants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of anticonvulsants include pyrimidinediones, fructose derivatives, aromatic allylic alcohols, valproylamides, carboxamides, bromides, and others. Pyrimidines are heterocyclic aromatic organic compounds found in nucleic acids, proteins, starches, and other biological molecules. Anticonvulsants are categorized into first-generation, second-generation, and third-generation drugs, and are available in various dosage forms such as capsules, tablets, liquids, rectal gel, among others. They find applications in treating conditions such as migraine, epilepsy, neuropathic pain, anxiety, fibromyalgia, bipolar disorder, and borderline personality disorder. These medications are utilized in diverse end-user industries, including hospitals, clinics, and others.

The anticonvulsants market research report provides anticonvulsants market statistics, including anticonvulsants industry global market size, regional shares, competitors with a anticonvulsants market share, detailed anticonvulsants market segments, market trends and opportunities, and any further data you may need to thrive in the anticonvulsants industry. This anticonvulsants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anticonvulsant market consists of sales of drugs such as phenobarbital, phenytoin, carbamazepine, levetiracetam, ethosuximide, clonazepam, diazepam, lorazepam, and midazolam. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.